Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.93 USD | -2.03% | +85.58% | +32.19% |
Jun. 06 | Top Premarket Gainers | MT |
Apr. 25 | Virax Biolabs Launches Portfolio of Immune Profiling Solutions Evaluating Adaptive Immunity in Post-Viral Syndromes at ESCMID Global 2024 | CI |
Financials (USD)
Sales 2022 | - | Sales 2023 | 8.56K | Capitalization | 10.81M |
---|---|---|---|---|---|
Net income 2022 | -1M | Net income 2023 | -5M | EV / Sales 2022 * | - |
Net cash position 2022 | 21.76K | Net cash position 2023 | 9.26M | EV / Sales 2023 | 182 x |
P/E ratio 2022 * |
-
| P/E ratio 2023 |
-1.35
x | Employees | 11 |
Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 73.2% |
1 day | -2.03% | ||
1 week | +85.58% | ||
Current month | +63.56% | ||
1 month | +141.25% | ||
3 months | +116.85% | ||
6 months | +12.67% | ||
Current year | +32.19% |
Managers | Title | Age | Since |
---|---|---|---|
James Foster
CEO | Chief Executive Officer | 37 | 12-12-31 |
Jason Davis
DFI | Director of Finance/CFO | 52 | 22-05-01 |
Mark Ternouth
CTO | Chief Tech/Sci/R&D Officer | 56 | - |
Members of the board | Title | Age | Since |
---|---|---|---|
Nelson Haight
BRD | Director/Board Member | 59 | - |
Evan Norton
BRD | Director/Board Member | 49 | - |
James Foster
CEO | Chief Executive Officer | 37 | 12-12-31 |
Date | Price | Change | Volume |
---|---|---|---|
24-06-10 | 1.93 | -2.03% | 861,398 |
24-06-07 | 1.97 | 0.00% | 2,501,275 |
24-06-06 | 1.97 | +84.11% | 79,771,600 |
24-06-05 | 1.07 | +1.90% | 1,246,832 |
24-06-04 | 1.05 | +0.96% | 327,307 |
Delayed Quote Nasdaq, June 10, 2024 at 04:00 pm EDT
More quotesChiffre d''affaires - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
+32.19% | 4.65M | |
+49.41% | 57.87B | |
+41.65% | 40.25B | |
-6.72% | 39.94B | |
-5.96% | 28.54B | |
+12.99% | 26.4B | |
-19.82% | 19.33B | |
+32.35% | 12.4B | |
-0.08% | 12.23B | |
+25.18% | 12.2B |
- Stock Market
- Equities
- VRAX Stock